Fibrillin-1 (FBN1) promotes gastric cancer progression by activating TGF-β1 and PI3K/Akt pathways, and is targeted by miR-486-5p to inhibit the growth of thyroid cancer cells (35, 36). Here, AKT1 is linked to thyroid gland carcinoma.